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Available online 30 March 2016AbstractPurpose: To review the current literature on ocular application of erythropoietin (EPO).
Methods: A comprehensive search was performed on Pubmed and Scopus databases. All selected articles were reviewed thoroughly by the
authors to review current applications of the EPO in ocular diseases.
Results: Various aspects of administration of EPO for different ischemic, traumatic, vascular, and degenerative disorders have been explained.
The articles are generally preclinical with few small studies reporting clinical outcomes.
Conclusion: EPO has been used for the treatment of different ophthalmic conditions with promising results. Further studies are needed to
elaborate the role of EPO in management of ocular diseases.
Copyright © 2016, Iranian Society of Ophthalmology. Production and hosting by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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4Introduction
Erythropoietin (EPO) is a 30.4 kDa hematopoietic glyco-
protein produced in the fetal liver and adult kidney. EPO is also
produced in low levels in central nervous system (CNS) tissue,
and the EPO receptor (EPOR) homodimer is expressed on most
CNS cell types, including neurons, astrocytes, and microglia.1
In fact, about 10% of EPO found in the bloodstream is of non-
renal origin.2 Historically, EPO has been known to promote
hematopoiesis and used routinely for the treatment of anemia in
clinical practice.3 In addition, angiogenic, anti-inflammatory
and endothelial cell stabilization effects of systemic EPO have
been previously described.4 In recent years, several studies have
shown neuroprotective and neurotrophic activities for the
EPO.5e8 Although the exact mechanism is not clear, EPO has
been shown to decrease the apoptosis, reactive oxygen species,
excitotoxicity, and inflammation, and increase the progenitorFinancial interest: The authors have no financial interest to declare.
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Bad, and Bcl-2/Bcl-xL by inhibiting formation of the Bax/Bcl
complex and reducing activation of effector caspases.9,10 EPO is
an interesting candidate not only for stroke treatment, but also
for delayed degenerative neurological conditions, such as
amyotrophic lateral sclerosis, Parkinson's, and Alzheimer's
disease.11,12 There is emerging evidence that EPO has an
important role in neuroprotection in the retina in addition to its
effect in the central nervous system.13 Expression of EPO and
EPOR has also been found in the retina.14
Recently, promising results have been reported using sys-
temic and intravitreal EPO for different ocular conditions.
This review presents evidence derived from experimental
studies in animals as well as human about the therapeutic
effects of EPO on ocular tissue.
Methods
A Pubmed and Scopus search was performed in October
2015 using each of the following key words: “Erythropoietin”,
“EPO”, “Eye”, and “Ocular”. All article types including
original articles, reviews, and case reports that described thesting by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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non-English articles were excluded. All selected articles were
reviewed thoroughly by the authors to review current appli-
cations of the EPO in ocular diseases.
ResultsPreclinical studies
Glutamate- and Nitric oxide-induced toxicity
Glutamate- and Nitric oxide-induced toxicity is involved in
glaucoma and ocular diseases caused by hypoxia and
ischemia, such as diabetic retinopathy. Retinal ganglion cells
(RGC) were isolated to test the neuroprotective effect of EPO,
and brain-derived neurotrophic factor (BDNF), which is a
potent neuroprotective agent, was used as a positive control.
While EPO could not substitute for BDNF in improving RGC
survival in serum free medium, it was useful in protecting
RGCs from glutamate- and Nitric oxide-induced toxicity.15 In
a cultured medium for neurocytes, EPO induced a stable
improvement of neurite outgrowth of retinal neurocytes. EPO
was effective in promoting the survival and decreasing the
apoptosis rates of the neurocytes suffering from glutamate-
induced cytotoxicity.16
Diabetic retinopathy
In early stages of the disease in the streptozotocin (STZ)-
induced diabetic rats, an increase in ganglion cells with swollen
mitochondria, retinal glutamate, andEPOR in the retinas occurs.
These changes can all be improved by intraperitoneal admin-
istered recombinant human erythropoietin (rhEPO).17 Exoge-
nous EPO administration by intravitreal injection in early
diabetes prevented retinal cell death and protected the blood-
retinal barrier function.18 A single intravitreal injection of
EPO (50 ng/eye) resulted in down regulation of EPOR, vascular
endothelial growth factor (VEGF), and its receptor (VEGFR) in
the diabetic rats. This effect persisted for at least 4 weeks.19 A
single intravitreal injection of EPO also produced therapeutic
effects on blood-retinal barrier (BRB) function and neuronal
survival at different time courses of retinopathy. The inhibition
of exogenous EPO on hypoxia induced factor (HIF) -1 alpha-
induced VEGF production in early diabetic retina may explain
in part the protective function of EPO toward reestablishment of
blood-retinal barrier integrity.20 These findings suggest the EPO
may be a useful agent for protection against progression of the
diabetic retinopathy at the very early stage by reducing blood
vessel degeneration.
Oxygen induced retinopathy (OIR)
EPO deficiency in heterozygous EPO-Tag transgenic mice
resulted in more profound retinal dysfunction due to OIR. The
dysfunction was detected by suppression in electroretinog-
raphy (ERG) amplitudes; however, the extent of retinal
ischemia, preretinal neovascularization, or neuroretinal
degeneration in OIR, was not affected. Systemic administra-
tion of recombinant EPO protected EPO-deficient mice against
this additional suppression.21Glaucoma
In a rat model of glaucoma induced by cautery of the
episcleral vessels, a single intravitreal 200 ng dose of EPO
was effective to prevent at least some of the elevated
pressure-induced loss of RGCs.22 Systemic administration of
rhEPO before or immediately after retinal ischemia induced
by an increase in intraocular pressure (IOP) reduced histo-
pathological retinal damage and promoted functional recov-
ery as assessed by electroretinography. Exogenous EPO also
significantly diminished terminal apoptotic events in the
ischemic retina, implying an anti-apoptotic mechanism of
action.23
Retinal detachment
Intravitreal injection of EPO in a rat model of retinal
detachment suppressed caspase-3 activation and enhanced
Bcl-XL expression, resulting in inhibition of apoptosis and
protection of photoreceptor cells.24
Axotomy
Genetic engineering was used to develop a transgenic
mouse line tg21 model that expresses human EPO prefer-
entially in neuronal cells without inducing polycythemia. In
this model, retina expresses human EPO and RGCs carry the
EPO receptor. Upon axotomy, the RGCs of EPO transgenic
tg21 mice were protected against degeneration, as compared
with wild-type control animals. This protective effect was
not only against acute, but also against slowly developing
neuronal injury. EPO-induced neuroprotection in vivo is
mediated by ERK-1/-2 signaling.25 After optic nerve trans-
action in adult rats, intravitreal EPO was both neuro-
protective and neuroregenerative for axotomized RGCs.
Moreover, a small proportion of axons regenerated up to
1 mm into the distal nerve.26
Retinopathy of prematurity (ROP)
In the rat model of ROP, anti-VEGF treatment led to
increased angiogenic signaling and recurrent intravitreal
neovascular growth. Local EPO signaling in the retina may
play a role in the formation of recurrent plaque-like
intravitreal neovascularization (IVNV) following bev-
acizumab.27 In addition to VEGF, EPO was found to be a key
factor in the pathogenesis of ROP, especially in the devel-
opment of neovascularization, suggesting a therapeutic pos-
sibility of EPO inhibitors in the ROP.28 In a rat model of
ROP, rhEPO penetrated into the eye in a dose- and time-
dependent manner. Although the 30,000 U/kg dose of
rhEPO increased, the ROP clock hour scores in ADPase-
stained tissues, 5000 U/kg rhEPO did not change the inci-
dence or severity of ROP by any measure. Considering the
beneficial effect of high-dose rhEPO against preterm brain
injury, the treatment may be instituted with minimal impact
on ROP.29
Photoreceptor protection
The direct neuroprotective effect of EPO on photorecep-
tors in the mouse model of retinal degeneration has been
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and represented the ability of EPO to diffuse through and
across the retina. Photoreceptor survival could prevent
Mu¨ller cell hypertrophy through decreased reactivity of glial
fibrillary acidic protein (GFAP) in the Mu¨ller cells.30 The
protective effects of systemic EPO on photoreceptors and the
retinal vasculature in rats could be due to multiple mecha-
nisms including regulation of retinal gliosis, increased infil-
tration of microglia into the retina, and inhibition of
p75NTR-pro-NT3 signaling in conjunction with stimulation
of production and mobilization of bone marrow-derived
cells.31 The point is that apoptotic mechanisms during
acute, light-induced photoreceptor cell death are different
from inherited retinal degeneration. Therefore, EPO alone is
not sufficient for a successful therapeutic intervention with
cell death in hereditary retinal degenerations.32
Age-related macular degeneration (ARMD)
Oxidative damage of the retinal pigment epithelium (RPE)
may play a role in the development and progression of ARMD.
RPE cells express the EPO receptor. Administration of EPO
either before radical exposure or shortly after radical exposure
of the cultured RPE cells remarkably reduced apoptosis rates.
Consequently, EPO should be evaluated as a potential candidate
for therapy and prevention of dry ARMD.33
Light-induced retinal apoptosis
Retinal expression of EPO and its receptor, protected RPE
cultured cells against daily light-induced, oxidatively medi-
ated retinal apoptosis and these stimuli increase EPO and
EPOR expression in cultured cells.34 Modulation of Akt1
phosphorylation, mitochondrial membrane potential, and
cysteine protease activity are the suggested mechanisms for
cytoprotection.35 A single intravitreal rhEPO injection with
the optimal dose of 5 U could postpone photoreceptor
apoptosis 24 h prior to light exposure to 5 h after.36
Optic neuritis
In rats suffering from optic neuritis, systemic application of
EPO significantly increased survival and function of RGCs.37
Assessment of retinal ganglion cells and optic nerves in a rat
model of multiple sclerosis revealed that neuron and axon
protection was most effective when EPO treatment that started
at immunization was combined with high-dose methylpred-
nisolone therapy given from days 1e3 of encephalomyelitis.
However, isolated neuronal or axonal protection without
clinical benefit was achieved under monotherapy with EPO or
methylprednisolone, respectively.38
Corneal epithelial erosions
EPO had no beneficial effect on the rate of healing of
corneal epithelial erosions in rabbit eyes, and the process may
be complicated by corneal stromal neovascularization.39
Safety of local injections
Intravitreal administration of EPO (at doses up to 625 ng)
in a rodent animal model did not affect retinal function asassessed by electroretinography (ERG). Moreover, single
intravitreal dosing did not elicit retinal neovascularization.40
Clinical examination, ERG, and pathologic evaluation
demonstrated that intravitreal delivery of EPO is safe, well
tolerated, and nontoxic to the intraocular structures at doses
from 0.6 U to 1000 U.41 Another study showed that intravitreal
injection of rhEPO in rabbit eyes was not associated with
adverse toxic effects up to 5000 IU doses.42 After subcon-
junctival injection, EPO reached all the neuroretinal cell layers
in the animal rat model after 24 h and was still present 60 h
after the administration.43Human studies
Diabetic retinopathy
The role of the EPO in diabetic retinopathy and diabetic
macular edema is not completely understood. Several studies
have reported higher levels of EPO in eyes of patients with
diabetic retinopathy. EPO and VEGF levels were measured in
the vitreous fluid of 73 patients with proliferative diabetic
retinopathy (PDR) and 71 patients without diabetes with the
use of radioimmunoassay and enzyme-linked immunosorbent
assay. They were reported to be independently associated with
proliferative diabetic retinopathy, and EPO was more strongly
associated with the presence of PDR than was VEGF.44
In another study, undiluted vitreous samples were obtained
from 24 patients with PDR and 20 patients with retinal
detachment, preretinal macular membranes, and macular
holes. The concentration of EPO was significantly higher in
patients with PDR than in the control group.45 In a compar-
ative study of aqueous samples of 28 patients with diabetic
macular edema, 59 patients with exudative ARMD, and 49
patients with cataract, eyes with diabetic retinopathy in
contrast to exudative age-related macular degeneration had
markedly increased aqueous humor levels of EPO.46 Similarly,
EPO concentrations were markedly higher in vitreous fluid
samples of 59 PDR patients compared to 16 macular holes.
When vitreous samples from 12 type 2 diabetic patients with
diabetic macular edema without significant retinal ischemia
and 12 PDR patients were compared with 10 nondiabetic
patients with macular holes, the EPO concentrations were
found to be strikingly higher in diabetic maculae edema. Also,
the EPO levels were found to be upregulated in diabetic pa-
tients even without retinopathy. These findings suggested that
other factors apart from ischemia are involved in the over-
expression of EPO in various stages of diabetic retinopathy47.
Although EPO blockade is likely to be beneficial for the
treatment of PDR, it may be hazardous for retinal diseases that
involve apoptosis of retinal photoreceptors.48 The possibility
that EPO might have a beneficial neuroprotective effect on
neuronal damage may be counterbalanced by the risk of
increased or the development of neovascularization for pa-
tients who also have retinal vasoproliferative diseases.45
Moreover, intravitreal injection of EPO may have other clin-
ical applications in diabetic retinopathy. To determine the ef-
fects of intravitreal injections of EPO in eyes with severe,
unresponsive diabetic macular edema, 5 eyes of 5 patients
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was subjectively improved by 3 or more lines in 3 eyes, and 1
line in 2 eyes was not highly correlated with anatomical
improvement.49 Another study reported elevated aqueous level
of EPO in 11 eyes of 11 patients with diabetic macular edema
in comparison with 10 eyes of 10 patients with cataract sur-
gery as controls. The EPO level was correlated with the level
of VEGF. After intravitreal EPO injection in diabetic eyes,
aqueous EPO levels were significantly elevated, whereas
aqueous VEGF levels were varied according to the time in-
terval since injection. The authors concluded that the effect of
intravitreal EPO in eyes with diabetic macular edema needs to
be further defined.50
In conclusion, clinical application and regulation of the
EPO/EPOR system will require careful dosing and better un-
derstanding of EPO/EPOR role in the pathogenesis of diabetic
retinopathy, so that vessel proliferation is inhibited without
impairment of neuronal survival.51
Glaucoma
In patients with chronic renal failure (CRF) undergoing
peritoneal dialysis (PD), retinal nerve fiber layer thickness
(RNFL) was found to be significantly reduced. In those pa-
tients who were treated with systemic EPO, RNFL parameters
were statistically significantly different from other patients in
the temporal quadrant. Therefore, EPO might be able to pre-
serve RNFL in patients with CRF undergoing PD in addition
to its hematopoietic properties.52 EPO is increased in the
aqueous humor of patients with primary acute angle-closure
glaucoma, primary chronic angle-closure glaucoma, primary
open-angle glaucoma (POAG), and neovascular glaucoma
(NVG).53,54 Analysis of the aqueous samples of 92 glaucom-
atous eyes (POAG, 40 eyes; pseudoexfoliative glaucoma, 26
eyes; NVG, 26 eyes) and 26 control eyes, showed higher
concentrations of EPO in glaucomatous eyes both with and
without controlled IOP. The aqueous level of EPO was re-
ported to be more proportionate to the level of IOP in eyes
with pseudoexfoliative glaucoma compared to eyes with
POAG and NVG.55 Another study, however, could not find any
difference between levels of EPO in aqueous humor and serum
in patients with pseudoexfoliation syndrome and pseu-
doexfoliative glaucoma, and controls.56 One study evaluated
the levels of EPO and soluble CD44 (sCD44) in the aqueous
and plasma of human eyes with POAG. The levels of both
biomarkers were significantly higher in patients compared to
the controls and a high positive correlation was found between
EPO and sCD44 in aqueous of POAG patients. A significant
correlation was also found between EPO or sCD44 levels and
severity of visual field loss. Although sCD44 had been
considered as a cytotoxic protein before, the authors proposed
that EPO and sCD44 may be useful proteins, with increased
levels in aqueous of POAG patients being a result of glaucoma
damage, not a cause.57
Methanol optic neuropathy
Two patients with methanol optic neuropathy were treated
with a combination of intravenous EPO, methylprednisolone,vitamin B12, vitamin B6, and folic acid. Both responded
dramatically to the treatment with a rapid recovery of vision.58
Optic neuritis
In a double-blind, placebo-controlled, phase 2 study, 20
patients with a first episode of optic neuritis were treated with
systemic EPO and compared with 17 placebo-treated patients.
RNFL thinning was less apparent after EPO treatment, and the
retrobulbar diameter of the optic nerve was higher in the EPO
group. Visual evoked potential (VEP) latencies at week 16
were shorter in EPO-treated patients, and visual functions
improved after EPO treatment.59 Contrary to this study,
another clinical trial showed that adding rhEPO to the intra-
venous methylprednisolone for the treatment of acute unilat-
eral optic neuritis of unknown or demyelinative origin had no
significant effect on visual acuity, perimetric, and OCT vari-
ables; however, an improvement in the perimetric mean de-
viation was noted.60
Pterygium
In an immunohistochemistry study on 9 surgically-excised
pterygia and 2 normal bulbar conjunctivas, the number of
EPOR-expressing epithelial cells was much higher in the
pterygium compared to the normal conjunctiva; however,
immunoreactivity for EPO was not noted in pterygium
epithelium and stroma, or in normal conjunctiva. Conse-
quently, EPO-independent EPOR-signaling pathway may play
a potential role in cell proliferation and angiogenesis in human
pterygium.61
Merkel cell carcinoma (MCC) of eyelid
In pathologic examination of 3 surgically-excised MCCs of
the eyelid, in spite of undetectable immunoreactivity of EPO,
an increased expression of EPOR was noted in the carcinoma
cells. These findings indicate that the EPO-EPOR pathway
plays an important role in the formation of MCC.62
Retinopathy of prematurity
In a retrospective chart review of infants with a birth weight
<1000 g, threshold retinopathy of prematurity occurred in
26.9% infants who received EPO, as compared with 13.5% of
those who did not receive it (OR 2.35). The authors proposed
that EPO is independently and significantly associated with
the development of the most severe stages of ROP in
extremely low birth weight neonates.63 Similarly, other studies
reported an increased risk of development and worsening of
ROP with EPO therapy.64e67 A systematic review on neonates
receiving rhEPO concluded that EPO initiated at less than 8
days of (postnatal) age may lead to a significant increase in the
risk of ROP.68
Retinal detachment
In a case report, the vitreous concentrations of EPO and
VEGF of an adolescent with a history of mild retinopathy of
prematurity who presented with a chronic retinal detachment
associated with neovascularization were measured by enzyme-
linked immunosorbent assays and compared with control
9K. Abri Aghdam et al. / Journal of Current Ophthalmology 28 (2016) 5e11levels. The EPO level was higher than those of patients with
PDR; however, the VEGF level was not as high as those of
patients with PDR. The authors speculated that EPO may have
roles in the prevention of apoptosis as well as neo-
vascularization in chronic retinal detachment.69
Another study reported the vitreous EPO level in 64 pa-
tients with rhegmatogenous retinal detachment (RRD) in
whom 13 had proliferative vitreoretinopathy (PVR) and
compared the results with patients with macular holes. The
mean level of EPO in the RRD group was significantly higher
than that in the idiopathic macular hole control group, and the
mean EPO level in PVR was higher than that in RRD, but the
difference was not significant.70
Retinal vein occlusion (RVO)
Similar to those found in diabetic retinopathy, the intraoc-
ular levels of EPO are increased in patients with RVO and
correlate with VEGF and the extent of macular edema. When
serum and vitreous concentration of EPO were measured from
6 patients with branch RVO, 6 patients with central RVO, and
12 control subjects, serum EPO levels did not differ between
the RVO and control groups; however, vitreal EPO was
elevated both in branch RVO and central RVO and correlated
well with vitreal VEGF and the level of central macular
edema.71 Similarly, higher aqueous EPO levels were found in
27 patients with macular edema secondary to recent onset
RVO compared to control subjects, and patients with central
retinal vein occlusion have higher EPO levels than those with
branch retinal artery occlusion. Moreover, a positive correla-
tion was found between the level of EPO and central macular
thickness and non-perfusion area.72 In contrast, in another
study on 12 patients with mild non-PDR and diabetic macular
edema (DME), 12 patients with RVO, 9 with central RVO, 3
with branch RVO, and 20 controls, EPO levels were found
higher in patients with DME and not elevated in patients with
macular edema secondary to RVO.73
Because of its role both in neuroprotection and angiogen-
esis, and similar to diabetic retinopathy, EPO might represent
an interesting target to investigate in patients with RVO.
Traumatic optic neuropathy
Intravenous injections of EPO resulted in a significant
improvement in visual acuity in 7 eyes with indirect traumatic
optic neuropathy compared to 8 patients with indirect trau-
matic optic neuropathy who had received no specific treat-
ment. Therefore, intravenous EPO might be evaluated as an
alternative treatment for indirect traumatic optic neuropathy.74
Non-arteritic anterior ischemic optic neuropathy (NAION)
In a prospective interventional case series, 31 eyes of 31
patients with NAION received intravitreal injection of EPO.
Six months after injections, visual acuity improved in 87%,
and 54.8% had 3 lines of visual improvement. A biphasic
pattern of response was observed with a decline in visual
acuity after initial response. The authors concluded that
intravitreal injection of EPO may be considered effective in
NAION.75Discussion
Ischemic, traumatic, or degenerative destruction of the
neurons is mediated by similar pathophysiological mecha-
nisms including apoptosis (programmed cell death), increased
release of excitotoxic amino acids (particularly glutamate),
intracellular accumulation of calcium, oxidative stress by
radical oxygen species, and inflammatory reactions accom-
panied by infiltration of cells and production of cytokines.
Neuroprotection aims to “halt or possibly reverse the common
pathway leading to neuronal cell injury or death” instead of
classical treatment modalities directed toward cure or allevi-
ation of specific disease etiologies.76 Consequently, neuro-
protection may be beneficial in glaucoma, vascular occlusions,
traumatic, ischemic, or degenerative retinal disorders.
Understanding the mechanism of action of EPO could give
rise to novel therapeutic strategies for the treatment of
neurodegenerative diseases and injuries. This is especially
important in the anti-VEGF era, since the treatment with
available anti-VEGFs is not always successful. Moreover,
application of anti-VEGF medications may change the balance
of other growth factors and cytokines. Systemic complications
of EPO including increased level of red blood cells and blood
pressure, and the risk of thrombotic and cardiac complications
should be remembered.4 The systemic administration of EPO-
derived peptides without capacity to raise hematocrit or to
worsen neovascularization but maintain tissue-protective
properties could be a promising approach. Because of the
excellent safety profile of intravitreal EPO, local administra-
tion may be a safe alternative to avoid possible systemic side
effects.
All available clinical experiences with EPO are from small
nonrandomized studies with low quality of evidence. Despite
this, ocular applications of EPO are encouraging. Large, ran-
domized, multi-center clinical trials with adequate sample size
and long follow-up times are required to clarify the potential
benefits of EPO in different ocular conditions.
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